Gribero (Dabigatran Etexilate Mesilate)

Gribero is indicated for several thromboembolic conditions where anticoagulation is required.

• Prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Treatment and secondary prevention of deep vein thrombosis (DVT).
• Treatment and secondary prevention of pulmonary embolism (PE).
• Post‑operative thromboprophylaxis after hip or knee replacement surgery, where approved.

The safety profile of Gribero includes both frequently observed and less common adverse events.

Common

• Dyspepsia or stomach discomfort.
• Minor gastrointestinal bleeding such as occult blood in stool.
• Nosebleeds (epistaxis).
• Headache.
• Dizziness.

Serious

• Major bleeding events, including intracranial or severe gastrointestinal hemorrhage.
• Allergic reactions such as rash, urticaria, or angioedema.
• Significant elevations in liver enzymes.
• Thrombotic complications if therapy is abruptly discontinued.

Before initiating Gribero, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess renal function; dose adjustment may be required in impaired clearance.
• Review history of bleeding disorders or recent major surgery.
• Consider age, especially patients over 75 years, who may have higher bleeding risk.
• Evaluate concomitant use of antiplatelet agents or NSAIDs.
• Counsel women of childbearing potential about unknown pregnancy safety.
• Monitor for signs of gastrointestinal ulceration or occult bleeding.

Gribero can interact with other medicines that affect hemostasis or drug metabolism.

Avoid

• Strong P‑glycoprotein (P‑gp) inhibitors such as ketoconazole, itraconazole, and ritonavir.
• Concurrent use of other anticoagulants (e.g., warfarin, heparin) or antiplatelet drugs (e.g., clopidogrel).

Use with caution

• Moderate P‑gp inhibitors like amiodarone or verapamil.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.
• Certain antifungal agents (e.g., fluconazole) that may raise dabigatran levels.